Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.
You may also be interested in...
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.
As wearable medical devices become increasingly common for more and more complex applications, developers are facing questions are about the industry’s direction and how they will protect consumers.